Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

NANot yet recruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
Chronic Kidney Disease(CKD)Type 2 DMType 2 Diabetes Mellitus (T2DM)
Interventions
OTHER

(IRIS-CKD Screening Program): Home Kit

"All participants approached for enrollment in Program 1 will receive National Kidney Foundational educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab(s) results.~Home Test Kit: a kit delivered to participants homes with instructions to complete eGFR (fingerstick) and/or UACR (urine sample) testing, depending on which lab(s) are missing at baseline."

OTHER

(IRIS-CKD Screening Program): Standard Lab Order

ll participants approached for enrollment in Program 1 will receive National Kidney Foundation educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab

Trial Locations (6)

27707

Duke University, Durham

37232

Vanderbilt University Medical Center, Nashville

55805

Essentia Health, Duluth

70121

Ochsner, New Orleans

76508

Baylor Scott & White, Temple

84107

Intermountain Health, Murray

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Duke University

OTHER